Solvay S A /adr/

• Palm Harbour Capital Q4 2023 Letter ↗ Palm Harbour Capital increased its Japanese allocation on expectations that stock-exchange pressure will improve capital allocation and shareholder engagement. The fund exited C Uyemura, Bayer and several other positions, while retaining both Solvay and Syensqo after their separation and building exposure to OCI’s asset-sale-driven value realization. fourth quarter 2023 SHBBF $9.1BSVYSF $2.9B4966 $2.2B +7
• Palm Harbour Capital Q2 2024 Letter ↗ Piraeus Port Authority anchors a contrarian portfolio case for competitively advantaged assets completing investment programmes while retaining substantial cash and scope for higher dividends. Palm Harbour argues that extreme megacap and AI enthusiasm has widened the opportunity in international value and small caps, while pressing SK Kaken to improve capital allocation. second quarter 2024 0OIY $1.5BGHTI LNA $289M +4
• Palm Harbour Capital Q1 2026 Letter ↗ Palm Harbour Capital sold Solvay and Magnum’s, reallocating capital to a Portuguese logistics business and a Korean eyecare company. It argues that Odet’s control structure and Bolloré dividend could enable further consolidation, and makes the case for Cirsa’s regulated gaming franchises, online expansion and acquisition-led growth. first quarter 2026 CIRSA $3.4B082920 $961M0NFS +6

All coverage of SVYSF →